Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass.
J Extra Corpor Technol
; 33(2): 117-25, 2001 May.
Article
in En
| MEDLINE
| ID: mdl-11467439
ABSTRACT
Heparin-induced thrombocytopenia (HIT) is described as an allergy-like adverse reaction to heparin. It is a potentially severe complication of heparin therapy that can result in serious or life-threatening venous or arterial thromboembolic events. In the United States, lepirudin (Aventis Pharma AG, Strasbourg, France) is an approved therapy for anticoagulation in patients with HIT requiring anticoagulation. Lepirudin is a recombinant form of hirudin, a leech enzyme that is a highly specific direct inhibitor of thrombin. Lepirudin monitoring during surgery can be managed with ecarin clotting time (ECT) (Cardiovascular Diagnostics, Inc., Raleigh, NC), which has recently been approved as a humanitarian device exemption (HDE) for use in the United States in the management of HIT with cardiopulmonary bypass. This case report describes a patient with HIT who was managed successfully with lepirudin and ECT during coronary artery bypass grafting.
Search on Google
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Hirudoterapia
Main subject:
Endopeptidases
/
Thrombocytopenia
/
Blood Coagulation Tests
/
Recombinant Proteins
/
Heparin
/
Cardiopulmonary Bypass
/
Hirudin Therapy
/
Anticoagulants
Country/Region as subject:
America do norte
Language:
En
Journal:
J Extra Corpor Technol
Year:
2001
Type:
Article
Affiliation country:
United States